SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
SciSparc Ltd. executive Adler Oz, the CEO and CFO, updated his initial insider ownership report. The amendment clarifies that his position includes 10,000 Ordinary Shares issuable from restricted share units vesting in quarterly installments of 1,250 shares through December 18, 2027, and 1,058 Ordinary Shares issuable from additional RSUs vesting in equal quarterly installments of 132 shares through June 20, 2026. The amendment also restates the derivative holdings table, showing a stock option for 6 Ordinary Shares with an exercise price of 31941.0000 and expiration on January 3, 2028. Following the reported holdings, Oz has 11,058 Ordinary Shares reported as directly owned, including the RSUs described.
SciSparc Ltd. director Revach Moshe filed an amended initial ownership report updating his beneficial holdings. Moshe now reports 3,649 Ordinary Shares directly owned, including 3,333 Ordinary Shares issuable from restricted share units (RSUs) vesting in quarterly installments of 417 shares through December 18, 2027, and 316 Ordinary Shares issuable from RSUs vesting in equal quarterly installments of 40 shares through June 20, 2026. Each RSU represents the right to receive one Ordinary Share. In addition, Moshe holds a stock option to acquire 1 Ordinary Share at an exercise price of 31,941, expiring January 3, 2028.
SciSparc Ltd. director Shay Amnon Ben filed an amended initial ownership report updating his equity holdings. The amendment states that he beneficially owns securities representing 3,649 Ordinary Shares, all issuable upon vesting of restricted share units that vest in quarterly installments through June 20, 2026 and December 18, 2027. He also holds a stock option giving the right to purchase 1 Ordinary Share at an exercise price of 31649.0000, expiring on January 3, 2028. The amendment replaces Table I and Table II of the prior Form 3 as to these ownership details.
SciSparc Ltd. updated the initial insider ownership report for director Alon Dayan. The amendment reflects beneficial ownership of 3,649 Ordinary Shares, including 3,333 RSUs vesting in quarterly installments of 417 shares through December 18, 2027, and 316 RSUs vesting in quarterly installments of 40 shares through June 20, 2026. It also adds a stock option for 1 Ordinary Share at an exercise price of 31941.0000, expiring on January 3, 2028, which was fully vested on April 21, 2024.
SciSparc Ltd. director Liat Sidi filed an amended Form 3 to update her initial ownership report. The amendment revises the total number of securities beneficially owned and restates Table II. Following this update, she holds 3,649 Ordinary Shares directly and a stock option over 1 Ordinary Share. Her holdings include 3,333 Ordinary Shares issuable from restricted share units vesting in quarterly installments of 417 Ordinary Shares through December 18, 2027, and 316 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 40 Ordinary Shares through June 20, 2026. Each RSU represents the right to receive one Ordinary Share.
SciSparc Ltd. director Weiss Amitay reports initial beneficial ownership details in an amended Form 3. Amitay holds 11,058 Ordinary Shares directly, including RSUs for 10,000 Ordinary Shares vesting in quarterly installments of 1,250 shares through December 18, 2027, and RSUs for 1,058 Ordinary Shares vesting in quarterly installments of 132 shares through June 20, 2026. Amitay also holds a stock option to buy 6 Ordinary Shares at an exercise price of 31,941.0000 per share, expiring January 3, 2028. The amendment restates the RSU footnote and Table II of the initial ownership report without reporting new buy or sell transactions.
SciSparc Ltd. director Lior Vider filed an amended initial ownership report updating his beneficial holdings. The amendment states that he beneficially owns 3,649 Ordinary Shares, which include (i) 3,333 Ordinary Shares issuable upon vesting of RSUs in quarterly installments of 417 shares through December 18, 2027, and (ii) 316 Ordinary Shares issuable upon vesting of RSUs in equal quarterly installments of 40 shares through June 20, 2026. The amendment also restates Table II to show a stock option directly held covering 1 underlying Ordinary Share at an exercise price of 31649.0000, exercisable from January 3, 2022 and expiring on January 3, 2028.
SciSparc Ltd. director Shrem Itschak filed an amended initial ownership report, updating disclosures of equity holdings and related footnotes. The amendment reports 11,058 Ordinary Shares held directly and a stock option over 6 Ordinary Shares at an exercise price of 31941.0000 per share, expiring January 3, 2028. It also clarifies that current holdings include 10,000 RSUs vesting in quarterly installments of 1,250 shares through December 18, 2027 and 1,058 RSUs vesting in quarterly installments of 132 shares through June 20, 2026, with each RSU representing one Ordinary Share.
SciSparc Ltd. reports updated equity holdings for Chief Technology Officer Adi Zuloff-Shani in an amendment to an earlier ownership statement. The amendment clarifies that the reported position represents 5,528 Ordinary Shares issuable upon the vesting of restricted share units, split between 5,000 RSUs vesting in quarterly installments of 625 shares through December 18, 2027 and 528 RSUs vesting in quarterly installments of 66 shares through June 20, 2026. It also restates option data, confirming a stock option covering 6 Ordinary Shares at an exercise price of 31941.0000, expiring January 3, 2028.